Curis Q2 net loss widens to $15.9M; appoints new CFO; emavusertib combo shows tumor reduction in 8 of 9

CURIS INC

2022-Q2 EPS reported -$0.35 revenue$4,450,000

Net loss of $15.9M ($0.17/sh) vs $10.8M ($0.12) in Q2 2021; revenue flat at $2.4M.
Cash and investments $107.2M as of June 30, 2022; cash runway expected into 2024.
Emavusertib + ibrutinib combo: tumor reduction in 8 of 9 evaluable patients; 2 CR, 2 PR; potential to overcome ibrutinib resistance.
Appointed Diantha Duvall as CFO effective Aug 5, 2022, succeeding Bill Steinkrauss (resigning).
Working with FDA to resolve partial clinical holds on emavusertib enrollment.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Diantha Duvall

Chief Financial Officer

CRIS · CURIS INC

Effective: 2022-08-05
Filed: August 4, 2022, 7:59 PM ET

On August 4, 2022, the Board of Directors (the “Board”) of the Company appointed Diantha Duvall to the position of chief financial officer, treasurer, assistant secretary, principal financial officer and principal accounting officer of the Company effective as of August 5, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Diantha Duvall was appointed as Chief Financial Officer at CURIS INC.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On August 4, 2022, the Board of Directors (the “Board”) of the Company appointed Diantha Duvall to the position of chief financial officer, treasurer, assistant secretary, principal financial officer and principal accounting officer of the Company effective as of August 5, 2022.

View on SEC.gov

CURIS INC filing history →

Source: SEC EDGAR

accession 0001193125-22-212487

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.